Intensity Therapeutics, Inc.
Intensity Therapeutics, Inc. (INTS) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · INTS · as of Sep 30, 2025
Ownership Breakdown
26
Institutional Holders
▼ 1 vs Q2
$721,188
Total Inst. Value
▲ $114,576 vs Q2
1.89M
Shares Outstanding
freeFloat 53.88%
2.96M
13F Shares Held
▲ 982,735 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
INTS largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
SAPIENT CAPITAL LLC biological products, (no diagnostic substances) | 976.8K | 28.81% | 28.81% | $239.71M | Oct 17, 2025 | — held |
SENTINUS, LLC biological products, (no diagnostic substances) | 481.2K | 14.19% | 14.19% | $116.78M | Nov 14, 2025 | ▲ 281.9K |
GEODE CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 258.9K | 7.63% | 7.63% | $62.83M | Nov 12, 2025 | ▲ 186.1K |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 255.9K | 7.55% | 7.55% | $62.19M | Nov 7, 2025 | ▲ 215.3K |
MESIROW FINANCIAL INVESTMENT MANAGEMENT, INC. biological products, (no diagnostic substances) | 200.0K | 5.90% | 5.90% | $48.54M | Nov 12, 2025 | ▲ 90.0K |
UBS GROUP AG biological products, (no diagnostic substances) | 136.2K | 4.02% | 4.02% | $33.10M | Nov 13, 2025 | ▲ 127.0K |
BROWN ADVISORY INC biological products, (no diagnostic substances) | 130.1K | 3.84% | 3.84% | $31.57M | Nov 14, 2025 | — held |
SIGMA PLANNING CORP biological products, (no diagnostic substances) | 69.2K | 2.04% | 2.04% | $16.79M | Nov 10, 2025 | — held |
WARBERG ASSET MANAGEMENT LLC biological products, (no diagnostic substances) | 60.0K | 1.77% | 1.77% | $14.56M | Nov 6, 2025 | ▼ 8.4K |
STONEBRIDGE FINANCIAL GROUP, LLC biological products, (no diagnostic substances) | 54.4K | 1.60% | 1.60% | $13.20M | Oct 20, 2025 | ▲ 37.9K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
10
Increased
+957.0K shares5
New Positions
first time holders1
Decreased
−8.4K shares6
Sold Out
fully exitedNet shares change (top 50)
+948.6K
+957.0K / −8.4K
Net new holders
+8
5 new / 6 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
INTS insider trading · insider activity
Source: SEC Form 4
9
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
BENDER LEWIS H President and CEO | Mar 26, 2026 | Award | 37,749 | $6.11 | $230.6K | 118.5K | Form 4 ↗ |
Wesolowski John M Principal Accounting Officer | Dec 31, 2025 | Award | 8,918 | $0.26 | $2.3K | 85.4K | Form 4 ↗ |
Talamo Joseph Chief Financial Officer | Dec 31, 2025 | Award | 14,482 | $0.26 | $3.8K | 28.7K | Form 4 ↗ |
Wesolowski John M Principal Accounting Officer | Jun 30, 2025 | Award | 69,745 | $0.26 | $18.2K | 76.4K | Form 4 ↗ |
Talamo Joseph Chief Financial Officer | Jun 30, 2025 | Award | 14,179 | $0.26 | $3.7K | 14.2K | Form 4 ↗ |
DUBIN THOMAS I H director | May 2, 2025 | Award | 50,000 | $0.57 | $28.5K | 50.0K | Form 4 ↗ |
Donovan Daniel director | May 2, 2025 | Award | 50,000 | $0.57 | $28.5K | 50.0K | Form 4 ↗ |
GOLDBERG MARK A director | May 2, 2025 | Award | 50,000 | $0.57 | $28.5K | 50.0K | Form 4 ↗ |
Leahy Emer director | May 2, 2025 | Award | 50,000 | $0.57 | $28.5K | 50.0K | Form 4 ↗ |
Wesolowski John M Principal Accounting Officer | May 2, 2025 | Award | 100,000 | $0.57 | $57.0K | 100.0K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Intensity Therapeutics, Inc. (INTS) is primarily owned by institutional investors, who hold approximately 100.0% of total shares outstanding. Company insiders own approximately 46.12%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Intensity Therapeutics, Inc. is SAPIENT CAPITAL LLC, holding approximately 976,797 shares — equal to 28.81% of outstanding shares — as of September 30, 2025.
A total of 26 institutional investors currently hold INTS stock, with a combined institutional value of approximately $721,188 as of the most recent 13F filing period.
Frequently asked questions
INTS ownershipIntensity Therapeutics, Inc. (INTS) is primarily owned by institutional investors, who hold approximately 100.0% of shares. The largest shareholder is SAPIENT CAPITAL LLC with a 28.81% stake. Company insiders hold 46.12%. Data sourced from SEC Form 13F as of September 30, 2025.